NCT07461831CompletedPhase 2
CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma
CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma: A Prospective, Single-Arm, Single-Center, Phase 2 Trial
Source: ClinicalTrials.gov · Last updated 30 Sept 2026
Brief summary (registry, in English)
CAR-T cell therapy targeting CD19 has been shown to be effective in heavily-pretreated B-cell ALL or NHL, but relapses post-CAR-T are common, and CD19 antigen loss is one of the reasons. Thus, the investigators supposed that CD19/CD22 bispecific CAR-T cell therapy would be more effective and less relapses would occur in B- NHL. In this prospective phase 2 clinical trial, the investigators aim to explore the efficacy and safety of CD19/CD22 bispecific CAR-T cell therapy in relapsed/refractory Large B cell lymphoma.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 74 (actual)
- First submitted
- 5 Mar 2026
- Start date
- 1 Feb 2022
- Primary completion date
- 18 Apr 2026
- Lead sponsor
- Beijing Tongren Hospital
- Diseases
- Childhood cancers
- NCT number
- NCT07461831
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 74
- From 1 Feb 2022 to the primary completion date, 18 Apr 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Uncontrolled active infection, HIV infection, syphilis serology reaction positive;
- Active hepatitis B or hepatitis C infection;
- With severe cardiac, liver, renal insufficiency, diabetes and other diseases;
Lab values
- Pregnant or lactating women (female participants of reproductive potential must have a negative serum or urine pregnancy test);
Other
- Participate in other clinical research in the past 4 weeks;
- Researchers think of that does not fit to participate in the study, or other cases that affect the clinical trial results.
Who the study is looking for
- 14 years to 85 years, expected survival \> 3 months;
- CD19 positive with or without CD22 positive Large B-cell lymphoma;
- relapsed or refractory disease;
- ECOG-PS score=0-2;
- Having at least one measurable lesion;
- Cardiac function: 1-2 levels;
- Liver: TBIL≤3ULN，AST ≤2.5ULN，ALT ≤2.5ULN;
- kidney: Cr≤1.25ULN;
- bone marrow: WBC ≥ 3.0×10e9/L, Hb ≥80 g/L, PLT ≥ 50×10e9/L;
- No serious allergic constitution;
- No other serious diseases that conflicts with the clinical program;
- No other cancer history;
- No serious mental disorder;
- Informed consent is signed by a subject or his lineal relation.
Age in the registry: 14 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beijing Tongren Hospital, Capital Medical University Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.